One promising candidate is D-2 hydroxyglutarate, a metabolite of mutant IDH, whose CSF concentration differs between patients with IDH-mutant and IDH-wild-type gliomas, as well as pre- and post-resection of IDH-mutant tumors [39, 109]. This evidence concerns the gene IDH1 and central nervous system cancer.